NAMS Stock Analysis: Buy, Sell, or Hold?
NAMS - NewAmsterdam Pharma Company N.V. Ordinary Shares
$22.80
0.94 (4.30%)
▲
5d:
-11.8%
30d:
-18.07%
90d:
-24.65%
WAIT
LOW Confidence
Analysis Updated: Sep 11, 2026 12:00 AM ET
Earnings: Nov 04, 2026
Smart Money Accumulation
Options open interest is building while the stock consolidates - a pattern consistent with institutional accumulation. View Scanner →
Signal fired Sep 9, 2026 at $23.31 · last confirmed Sep 9, 2026
Strength: 7.5/10
Get Alerted When NAMS Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR STABILIZATION: NAMS is down 11.8% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
⏸️ WAIT FOR STABILIZATION: NAMS is down 11.8% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
In-depth Analysis How we analyze
Valuation Analysis: NAMS is currently trading at $22.80, which is considered oversold relative to its 30-day fair value range of $24.84 to $28.13.
Technical Outlook: Technically, NAMS is in a downtrend. Immediate support is located at $21.23, while resistance sits at $26.88. The stock is showing strong short-term momentum, up 4.3% recently.
Market Sentiment: NAMS scores 25/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $51.49 (+125.8%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, NAMS is in a downtrend. Immediate support is located at $21.23, while resistance sits at $26.88. The stock is showing strong short-term momentum, up 4.3% recently.
Market Sentiment: NAMS scores 25/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $51.49 (+125.8%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$24.84 -
$28.13
Company Quality Score
41/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
63.2%
Protect Your Profits
Holding NAMS? Use our AI-powered strategies to protect your downside while keeping your long-term position.
View Profit Protection PlanAll Signals
- BULLISH: Price oversold vs 30-day range
- BEARISH: Weak technical setup (25/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+4.3%)
- BULLISH: Trading 125.8% below Wall St target ($51.49)
- WARNING: Composite score 41/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$24.84 -
$28.13
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$21.23
Resistance Level
$26.88
Current Trend
Downtrend
Technical data as of
Sep 11, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-14.86
Wall Street Target
$51.49
(+125.8%)
Revenue Growth (YoY)
-80.7%
Share & Embed Analysis
Last updated: September 12, 2026 2:06 PM ET
Data refreshes hourly during market hours. Next update: 3:06 PM
Data refreshes hourly during market hours. Next update: 3:06 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is NAMS showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
DNLI
Denali Therapeutics Inc |
STRONG BUY
19 analysts |
$36 | 45 HOLD |
|
RNA
Atrium Therapeutics, Inc… |
STRONG BUY
15 analysts |
$25 | 55 HOLD |
|
JSPR
Jasper Therapeutics Inc |
STRONG BUY
11 analysts |
$7 | 62 BUY |
|
RLAY
Relay Therapeutics Inc |
STRONG BUY
13 analysts |
$27 | 64 BUY |
|
MIRM
Mirum Pharmaceuticals Inc |
STRONG BUY
10 analysts |
$138 | 59 HOLD |
Advanced NAMS Option Strategies
Professional options setups generated by AI based on today's NAMS price and gamma walls.
